Moderna 1273
Omicron BA.1 – containing mRNA 1273 boosters compared with the original Covid-19 vaccine in the UK : a randomised, observer blind, active controlled trial
Overview / Background
Process
From Feb 16 – March 24 2022 > 3000 participants worldwide were randomised to receive the 50ug Omicron BA.1 monovalent vaccine or the original 50ug mRNA-1273 ( Spikevax) vaccine ( active control) as boosters ( 1:1 ratio) . Between April 2 and June 17 2022 participants were randomly allocated to receive the 50ug Omicron bivalent booster or the 50ug mRNA-1273 ( active control) . Participants were age stratified 16-<65y and >65y ) Participants were followed up for 1 year . Neutralising Antibodies for SARs-CoV-2 and safety events were monitored .
Outcome
The Omicron BA.1 variant monovalent and bivalent boosters showed superior neutralising antibodies against the Omicon BA.1 variant compared with the original mRNA-1273 booster . The bivalent vaccine showed modest benefit against the monovalent vaccine. Results were comparable regardless of previous SARs -CoV-2 infection status . Incidents of adverse reactions were similar to those observed previously for mRNA-1273
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00295-5/fulltext
Wansford Target 150 participants
Actual recruitment 230 participants
Process
Outcomes
Additional Information
Recruitment
Get Involved
This study has now concluded.
Would you like to participate in an upcoming study?
Click below to send us your details and a member of the team will be in touch.
